Given that GLP-1-RAs alter gut motility and secretion, and that the gut microbiota can influence host eating behavior, including food preferences, it is plausible that these drugs indirectly influence taste perception by modulating microbial composition and the subsequent production of metabolites that can signal to the brain, potentially via vagal afferents or systemic circulation
The continued strength of this route stems from its superior efficacy, durable outcomes, and expanding reimbursement for high-performing injectable therapies
Compounded GLP-1s have not been evaluated by the FDA, but side effects are expected to be similar to other GLP-1-based medications reviewed by the FDA, which have the following side effects: nausea, diarrhea, vomiting, constipation, abdominal (stomach) pain, headache, fatigue, dyspepsia (indigestion), dizziness, abdominal distension, eructation (belching), hypoglycemia (low blood sugar), flatulence (gas buildup), gastroenteritis (an intestinal infection), and gastroesophageal reflux disease (a type of digestive disorder)
Health system specialty pharmacies (HSSP) play a critical role in overcoming these obstacles and improving patient outcomes associated with GLP-1 therapy